Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 6/20 | 0.48 |
| ▸ | TK1 | P04183 | 7/20 | 0.46 |
| ▸ | CA12 | O43570 | 9/20 | 0.41 |
| ▸ | CA2 | P00918 | 9/20 | 0.41 |
| ▸ | CA5A | P35218 | 9/20 | 0.41 |
| ▸ | CA7 | P43166 | 9/20 | 0.41 |
| ▸ | CA9 | Q16790 | 9/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 9/20 | 0.41 |
| ▸ | CA1 | P00915 | 7/20 | 0.41 |
| ▸ | TERT | O14746 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13169197 | 0.76 | TK1 (0.43) | TK2TK1 | |
| SCHEMBL12718550 | 0.75 | RNASE1 (0.35) | TK1 | |
| SCHEMBL12749183 | 0.75 | TK2 (0.78) | TK2TK1CA12CA2CA5A | |
| SCHEMBL12718176 | 0.75 | TK2 (0.78) | TK2TK1CA12CA2CA5A | |
| SCHEMBL12718571 | 0.74 | RNASE1 (0.34) | TK1 | |
| SCHEMBL12718570 | 0.72 | RNASE1 (0.33) | — | |
| SCHEMBL13949130 | 0.72 | RNASE1 (0.36) | TK2TK1 | |
| SCHEMBL26941474 | 0.72 | LMNA (0.54) | TK1 | |
| SCHEMBL16158115 | 0.70 | TK1 (0.36) | TK1 | |
| SCHEMBL19749043 | 0.67 | LMNA (0.32) | TK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928210-B2 | Nucleoside based proliferation imaging markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090016958-A1 | Nucleoside based proliferation imaging markers | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090016958-A1 | Nucleoside based proliferation imaging markers | MKI67, SLC29A1, SLC29A2 | TK2 20/4885TK1 4/4885CA12 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.